阿昔替尼在肾细胞癌治疗中的临床研究进展

Axitinib in the treatment of renal cell carcinoma

摘要:

靶向治疗在肾癌治疗中起重要作用，以血管内皮生长因子及其受体为靶点的酪氨酸激酶抑制剂 是关键的靶向治疗药物之一。小分子酪氨酸激酶抑制剂阿昔替尼高选择性地抑制血管内皮细胞生长因子受体 酪氨酸激酶的活性，阻断血管内皮细胞生长因子与其受体结合，抑制肿瘤血管生成。阿昔替尼与免疫检查点 抑制剂联合治疗晚期肾癌疗效可观。该文就阿昔替尼在肾癌治疗中相关研究进展作一综述。

Abstract:

Targeted therapy plays an important role in the treatment of renal cancer, among which TKI targeting vascular endothelial growth factor and its receptor is one of the key targeted therapeutic drugs. Small molecule TKI Axitinib highly selectively inhibits the activity of VEGFR tyrosine kinase, blocks the binding of VEGF to its receptor, and inhibits tumor angiogenesis. Clinical studies have shown that the combination of Axitinib and checkpoint inhibitors in the treatment of advanced renal cancer is effective. In this paper, the relevant studies on the treatment of renal cancer with Axitinib were analyzed and summarized.